Dexcom Inc SEC Filings

DexCom (DXCM) reported insider purchases by its President & COO, Jacob Steven Leach. On 11/10/2025, he bought 15,700 shares at a weighted average price of $54.977 and 2,500 shares at a weighted average price of $55.4252, executed in multiple trades within disclosed price ranges.

Following these transactions, he directly beneficially owned 331,697 shares. That total includes 84,537 unvested restricted stock units scheduled to vest through March 2026–2028 as previously granted. In addition, 47,296 shares are indirectly held through the Gregg Family Grandchildren's Trust, for which his spouse serves as a trustee.

Dexcom (DXCM) insider activity: Director Richard A. Collins, through the Richard A. Collins Revocable Trust, sold 3,948 shares of common stock on 11/10/2025 at $55.17 per share, pursuant to a Rule 10b5-1 plan adopted on August 7, 2025.

Following the sale, 37,994 shares are beneficially owned indirectly by the Trust. In addition, 5,074 unvested RSUs granted on May 8, 2025 will vest on the earlier of the one-year grant anniversary or DexCom’s 2026 Annual Meeting of Stockholders.

Dexcom delivered strong Q3 2025 results, led by higher disposable sensor volumes. Revenue reached $1,209.3 million, up 22% year over year, with gross profit of $731.4 million and operating income of $242.5 million. Net income rose to $283.8 million, and diluted EPS was $0.70, compared to $0.34 a year ago.

Margins benefited from higher manufacturing volumes and lower legal expenses, partially offset by pricing headwinds and production inefficiencies. Other income improved on gains from equity investments. Operating cash flow was $659.9 million for the quarter, supporting a strong liquidity position; cash, cash equivalents and short‑term marketable securities totaled $3.32 billion at quarter end.

The company repurchased 2.4 million shares for $187.2 million under its $750 million authorization. U.S. revenue was $851.9 million (70% of total), with International at $357.4 million (30%). Dexcom noted a tax benefit from its Malaysia tax holiday. Convertible notes outstanding remained at $2.46 billion principal with low coupons, and no conversions were reported.

Dexcom, Inc. (DXCM) furnished an 8‑K to announce financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1.

The company stated that the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The submission also includes the Cover Page Interactive Data File (Inline XBRL).

Dexcom, Inc. (DXCM) reported that director Euan Ashley acquired 7,166 restricted stock units on 10/24/2025 via a Form 4 filing.

The RSU grant was recorded at a $0 price and is scheduled to vest in three equal annual installments from the grant date. Following this transaction, the reporting person beneficially owned 7,166 shares, held with direct ownership.

Dexcom, Inc. (DXCM) — Initial insider ownership filing. Director Euan Ashley filed a Form 3 reporting no securities beneficially owned as of 10/24/2025. The filing is made by one reporting person and marks the initial statement of holdings for this insider role. A Power of Attorney (Exhibit 24) authorized the signature by an attorney-in-fact.

Dexcom expanded its Board and added new expertise. On October 24, 2025, the Board increased its size to ten directors and appointed Dr. Euan Ashley as a director, effective immediately, with a term expiring at the 2026 annual meeting. He joins the Nominating and Governance Committee and the Technology Committee; Kyle Malady steps down from the Nominating Committee and remains Technology Committee chair.

The Board also approved increasing the Board to eleven directors effective January 1, 2026, and confirmed the previously announced appointment of Jacob S. Leach effective that date, contingent on continued service. Dr. Ashley was deemed an independent director and received an initial $500,000 RSU grant vesting over three years, and will be eligible for an annual $345,000 RSU grant around the 2026 annual meeting; non‑employee director awards accelerate upon a change in control.

DexCom, Inc. announced that its Chief Executive Officer and Chairman, Kevin R. Sayer, has taken a temporary medical leave of absence effective September 14, 2025. To ensure continuity, the Board appointed Jacob S. Leach, the company’s President and Chief Operating Officer, to serve as interim principal executive officer while retaining his current responsibilities.

The Board also named Mark Foletta, the Lead Independent Director, as interim chairman of the Board. Neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles. The company states there is no special arrangement under which Mr. Leach was selected, no family relationships between him and other directors or executives, and no related-party transactions involving him that require disclosure.

Kyle Malady, a director of DexCom, Inc. (DXCM), reported a sale of common stock executed on 09/05/2025 under a previously adopted 10b5-1 trading plan. The Form 4 shows 667 shares were sold at $80.86 per share pursuant to the 10b5-1 plan adopted on 06/06/2025 to allow orderly dispositions. After the reported sale, Mr. Malady beneficially owned 22,667 shares, which include 5,192 unvested restricted stock units granted on 05/08/2025 that vest on the earlier of the one-year anniversary of the grant or DexCom’s 2026 Annual Meeting of Stockholders.